Home LiteratureArticle Details
PMID: 27906681 Published · ppublish English Journal Article

siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration.

Oncotarget ·Vol. 8 ·No. 2 ·2017-01-10 ·Pages 2585-2593

JingSong H, Hong G, Yang J, Duo Z, Li F, WeiCai C, XueYing L, YouSheng M, YiWen O, Yue P, Zou C

Abstract

Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. Collagen type IV alpha 2 (COL4A2), a major component of the basement membrane, dynamically influences a wide range of biological processes, including cancer pathogenesis and progression. This study evaluated the effects of COL4A2 siRNA delivered by lentiviral vector to TNBC cells. COL4A2 siRNA lenti-viral vector was constructed and transfected into MDA-MB-231 and MDA-MB-468 cells. The COL4A2 mRNA levels were quantified by RT-PCR. CCK8 assay was performed to evaluate cell proliferation and migration. Cell migration and invasion assays were carried out using Transwell. Cell apoptosis and cell cycle analyses were conducted using flow cytometric approach. We found that COL4A2 mRNA levels were significantly down-regulated in MDA-MB-231 and MDA-MB-468 cells after transfection with COL4A2 siRNA. Furthermore, cell migration and proliferation were significantly decreased and the cell cycle was arrested. Our results indicated that COL4A2 siRNA significantly suppresses the migration and proliferation of TNBC cells. Inhibition of COL4A2 may be a new target for the prevention and treatment of TNBC.

Keywords
COL4A2 lentiviral vector small interfering RNA (siRNA) triple-negative breast cancer (TNBC)
MeSH Terms
Apoptosis Cell Line, Tumor Cell Movement Cell Proliferation Collagen Type IV/genetics Female Gene Expression Regulation, Neoplastic Gene Silencing Humans RNA, Small Interfering/pharmacology Triple Negative Breast Neoplasms/genetics Up-Regulation
Chemicals
COL4A2 protein, human Collagen Type IV RNA, Small Interfering
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
JingSong He
Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, 518035, China.
Hong Guan
Department of Pathology, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen 518035, China.
Yang Jianbo
Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, UMN Twin Cities, MN 55455, USA.
Duo Zheng
Shenzhen Key Laboratory of Translational Medicine of Tumor, Department of Cell Biology and Genetics, School of Medicine, Shenzhen University, Shenzhen, Guangdong, 518060, China.
Li Fu
Department of Pharmacology, Shenzhen Key Laboratory of Translational Medicine of Tumor and Cancer Research Centre, School of Medicine, Shenzhen University, Shenzhen, 518060 China.
WeiCai Chen
Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, 518035, China.
XueYing Luo
Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, 518035, China.
YouSheng Mao
Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, 518035, China.
YiWen OuYang
Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, 518035, China.
Yue Pan
Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, 518035, China.
Zou Chang
Clinical Medical Research Center, Shen Zhen People's Hospital, The Second Clinical Medical College of Jinan University, 518020, China.
References (29)
29 references, click to expand
  1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
    Int J Cancer. 2015 Mar 1;136(5):E359-86 PMID: 25220842
  2. Breast cancer statistics and markers.
    J Cancer Res Ther. 2014 Jul-Sep;10(3):506-11 PMID: 25313729
  3. Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2.
    Mol Cancer Res. 2015 Jan;13(1):78-85 PMID: 25169943
  4. Triple-negative breast cancer.
    N Engl J Med. 2010 Nov 11;363(20):1938-48 PMID: 21067385
  5. Genome-wide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas.
    PLoS One. 2013 Jun 20;8(6):e66632 PMID: 23818951
  6. A panel of genes methylated with high frequency in colorectal cancer.
    BMC Cancer. 2014 Jan 31;14:54 PMID: 24485021
  7. Hemocyte-secreted type IV collagen enhances BMP signaling to guide renal tubule morphogenesis in Drosophila.
    Dev Cell. 2010 Aug 17;19(2):296-306 PMID: 20708591
  8. Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention.
    Circulation. 2015 May 5;131(18):1555-65 PMID: 25753534
  9. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.
    Biochem Biophys Res Commun. 2013 Sep 20;439(2):275-9 PMID: 23973711
  10. Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China.
    Oncotarget. 2015 Jun 30;6(18):16757-65 PMID: 26158290
  11. Screening for key genes associated with invasive ductal carcinoma of the breast via microarray data analysis.
    Genet Mol Res. 2014 Sep 29;13(3):7919-25 PMID: 25299107
  12. Targeting triple-negative breast cancer: optimising therapeutic outcomes.
    Ann Oncol. 2012 Sep;23 (9):2223-34 PMID: 22517820
  13. A combined approach identifies three mRNAs that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
    J Cancer Res Clin Oncol. 2012 Dec;138(12):2127-36 PMID: 22864815
  14. COL4A2 mutation associated with familial porencephaly and small-vessel disease.
    Eur J Hum Genet. 2012 Aug;20(8):844-51 PMID: 22333902
  15. Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids.
    Oncol Rep. 2014 Aug;32(2):641-9 PMID: 24927163
  16. Diagnostic marker signature for esophageal cancer from transcriptome analysis.
    Tumour Biol. 2016 May;37(5):6349-58 PMID: 26631031
  17. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
    PLoS One. 2015 Jun 23;10(6):e0129842 PMID: 26103053
  18. Functional interaction between COL4A1/COL4A2 and SMAD3 risk loci for coronary artery disease.
    Atherosclerosis. 2015 Oct;242(2):543-52 PMID: 26310581
  19. Molecular subtypes in breast cancer evaluation and management: divide and conquer.
    Cancer Invest. 2008 Feb;26(1):1-10 PMID: 18181038
  20. Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development.
    Dev Biol. 1991 Feb;143(2):303-8 PMID: 1991553
  21. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ.
    Oncogene. 2013 Oct 10;32(41):4892-902 PMID: 23178494
  22. COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke.
    Am J Hum Genet. 2012 Jan 13;90(1):91-101 PMID: 22209247
  23. Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy.
    Cell Cycle. 2013 Sep 1;12(17):2705-6 PMID: 23966168
  24. Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes.
    Hum Mutat. 2011 Feb;32(2):127-43 PMID: 21280145
  25. De novo and inherited mutations in COL4A2, encoding the type IV collagen α2 chain cause porencephaly.
    Am J Hum Genet. 2012 Jan 13;90(1):86-90 PMID: 22209246
  26. Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.
    Tumour Biol. 2016 Jan;37(1):1173-82 PMID: 26277786
  27. Triple-negative breast cancer: making the most of a misnomer.
    Asia Pac J Clin Oncol. 2012 Jun;8(2):145-55 PMID: 22524573
  28. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.
    Ann Oncol. 2012 Aug;23 Suppl 6:vi19-22 PMID: 23012297
  29. Type IV collagens regulate BMP signalling in Drosophila.
    Nature. 2008 Sep 4;455(7209):72-7 PMID: 18701888
Article Info
Journal
Oncotarget
Abbr.
Oncotarget
ISSN
1949-2553
DOI
10.18632/oncotarget.13716
Published
2017-01-10
Pages
2585-2593
Language
English
Region
United States
NLM ID
101532965
PMCID
PMC5356825
Subset
IM
External Links
PubMed source DOI: 10.18632/oncotarget.13716 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2